Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Gyre Therapeutics (L9S) Stock Price & Analysis

L9S Stock Chart & Stats

€5.75-€0.60(-9.45%)
At close: 1:00 AM GMT+1
€5€5.2€5.41 Jun8 Jun
Day’s Range
EUR 5.75 - EUR 5.75
52-Week Range
EUR 4.74 - EUR 7.65
Previous Close
EUR 6.35
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 432.46M
Enterprise Value
EUR 648.81M
Total Cash (Recent Filing)
EUR 74.80M
Total Debt (Recent Filing)
EUR 3.42M
Price to Earnings (P/E)
―
Beta
0.87
Next Earnings
Nov 18, 2026 (Est.)
EPS Estimate
-0.1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Gross Profitability

A roughly 94% gross margin indicates strong economics on products already generating revenue and provides substantial room to fund operating activities. This supports reinvestment in the pipeline and offers a durable foundation for improving profitability if operating costs become better controlled.

Conservative Balance Sheet

Very low leverage and a sizable equity base reduce near-term balance-sheet pressure and preserve flexibility for clinical development, commercialization, and other strategic investment. This financial cushion is particularly valuable for a biotechnology company funding several programs with uncertain timing.

Capital-Efficient Pipeline Funding

Using established China commercial operations to support research can reduce reliance on external capital while advancing multiple oncology and inflammatory disease programs. This model may improve development resilience by linking current revenue generation with longer-term pipeline investment.

Bears Say

Return To Net Losses

The return to a material net loss after positive net income in 2024 and 2025 shows that revenue growth is not currently translating into durable bottom-line profitability. Continued losses could constrain internal funding capacity and increase dependence on successful future execution.

Unreliable Core Cash Conversion

Negative operating cash flow indicates that reported business activity is not consistently converting into cash from operations. Although recent free cash flow improved, the uneven history, including negative operating and free cash flow in 2024, raises execution and funding reliability concerns.

Earnings Volatility

Large swings between losses and modest profitability make the company’s earnings power difficult to assess and reduce confidence in near-term financial durability. Such volatility can complicate budgeting, capital allocation, and the sustained funding of clinical programs.

Gyre Therapeutics News

L9S FAQ

What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was €4.74 and its highest was €7.65 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is €432.46M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s next earnings report is estimated for Nov 18, 2026 (not yet confirmed), which is in 16 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on Aug 07, 2026. The company reported -€0.104 earnings per share for the quarter, missing the consensus estimate of -€0.049 by -€0.054.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics does not currently pay dividends.
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is -0.10.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 106,033,760 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of -€0.104 in its last earnings report, missing expectations of -€0.049. Following the earnings report the stock price went up 1.852%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in DE:L9S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology